Safety of leukotriene receptor antagonists in pregnancy

Bakhireva, Ludmila N.; Jones, Kenneth Lyons; Schatz, Michael; Klonoff-Cohen, Hillary; Johnson, Diana; Slymen, Donald J.; Chambers, Christina D.

doi:10.1016/j.jaci.2006.12.618

Cited by 100 publications

(44 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One such drug group is leukotriene receptor antagonists, e.g., montelukast. Previous studies [16,17] were based on few exposures (96 and 180, with five and one infant with major malformations, respectively). The present material contained 512 exposed infants among which 17 had a relatively severe malformation.…”

Section: Discussionmentioning

confidence: 99%

Maternal Asthma and Use of Antiasthmatic Drugs in Early Pregnancy and Congenital Malformations in the Offspring

Källén¹

2014

J Pulm Respir Med

View full text Add to dashboard Cite

Objectives: To investigate the risk of congenital malformations in infants born of women who had used antiasthmatic drugs in early pregnancy.Methods: Data were obtained from the Swedish Medical Birth Register for 1996-2011. Information on drug use was based on midwife interviews towards the end of the first trimester. Presence of congenital malformations was ascertained from three national health registers. Risk estimates were made with Mantel-Haenszel odds ratios after adjustment for delivery year, maternal age, parity, smoking, and body mass index. Consideration was taken to concomitantly used drugs.Results: Among more than 1.5 million women who gave birth, 2.9% reported the use of antiasthmatics. These women had characteristics which distinguished them from other women who gave birth and they more often than these used other drugs than antiasthmatics. These differences seemed to affect malformation risk only little. The risk for a major malformation was slightly but significantly increased (odds ratio=1.09, 95% confidence interval 1.03-1.12), specifically this was seen for cardiovascular defects, median cleft palate, and pyloric stenosis. There was no specific association with specific drugs or drug groups, the highest risk estimate was seen for women who used only one drug and notably a short-acting adrenergic or used three or more antiasthmatic drug groups. Conclusion:The absolute risk for a congenital malformation in infants born of women using antiasthmatics is low and some evidence indicates that it is due to underlying asthma. A good control of asthma seems important and scare of teratogenicity of the common antiasthmatic drugs should not prevent adequate use.

show abstract

Section: Discussionmentioning

confidence: 99%

Maternal Asthma and Use of Antiasthmatic Drugs in Early Pregnancy and Congenital Malformations in the Offspring

Källén¹

2014

J Pulm Respir Med

View full text Add to dashboard Cite

show abstract

“…According to the manufacturer pregnancy registry including several hundreds of patients, 19 cases of congenital anomalies were reported until July 2009 with montelukast [62] . Limb reduction defects were present in 6 montelukast-exposed children, but this association was not confirmed in a large database study [64] or in 3 other studies that did not report any increase in perinatal complications or congenital malformations [65,66] . Leukotriene antagonists should be considered as a second-line treatment during pregnancy, and, when needed, the best investigated leukotriene antagonist montelukast should be preferred ( table 3 ).…”

Section: Leukotriene Antagonistsmentioning

confidence: 91%

Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients

Panchaud

Paolo²,

Koutsokera³

et al. 2016

Respiration

View full text Add to dashboard Cite

Health management of cystic fibrosis (CF) patients should be maximized during pregnancy and breastfeeding because of its significant impact on the maternal and newborn outcomes. Thus, numerous drugs will have to be continued during pregnancy and lactation. Most of the drugs representing CF treatment lines cross the placenta or are excreted into human milk. Research addressing the risks and benefits of drugs used in CF patients during pregnancy and lactation is often incomplete or challenged by limited methodology, which often leads to conflicting or inconclusive results. Yet, potential treatment benefits for CF pregnant patients most often outbalance potential risks for the unborn child.

show abstract

“…The study demonstrated that the use of LTRAs in pregnancy was not associated with a specific pattern of major structural anomalies in offspring, or a large risk of other adverse perinatal outcomes. However, results should be interpreted with caution because of limited sample sizes [143].…”

Section: Pregnancymentioning

confidence: 98%